S&P 500 falls on pressure from retail stocks, weak jobless claims
In a challenging market environment, Immunome Inc (NASDAQ:IMNM) stock has touched a 52-week low of $8.97, though InvestingPro analysis shows analysts maintain a strong buy rating with price targets ranging from $21 to $38. The biopharmaceutical company, which focuses on harnessing the human immune system to develop therapies for cancer and infectious diseases, has seen a significant downturn over the past year. Investors have witnessed a stark decrease in the value of their holdings, with Immunome’s stock plummeting by -60.4% over the one-year period. Despite the decline, the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 6.17. InvestingPro data reveals 12 additional key insights about IMNM’s financial health and growth prospects, available to subscribers.
In other recent news, Immunome, Inc. has announced a preliminary financial estimate, expecting to report approximately $217.3 million in cash, cash equivalents, and marketable securities as of December 31, 2024. This estimate is preliminary and may change following the completion of financial closing procedures. In addition, Immunome disclosed plans for a public stock offering valued at $125 million, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities acting as joint book-running managers. The offering is subject to market conditions, and underwriters have a 30-day option to purchase additional shares.
In a related development, Immunome has priced an upsized public offering of common stock at $7.75 per share, aiming to raise approximately $150 million before expenses. The funds from these offerings are intended to support the company’s ongoing research and development projects. Furthermore, Immunome’s pipeline includes several promising candidates, such as varegacestat, currently in a Phase 3 trial for desmoid tumors, and IM-1021, with a Phase 1 trial expected to begin in early 2025.
Additionally, Immunome has announced a significant relocation package for its Chief Financial Officer, Max Rosett, which includes a total of $400,000 in bonuses to facilitate his move to Bothell, Washington. This move reflects Immunome’s commitment to strengthening its executive team as it advances its strategic objectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.